A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics
- 05 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 05 Mar 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated